Study study type
PathologyT1T0Patientssample sizesROB Results

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus lapatinib
lapatinib plus trastuzumab
EGF104900, 2010
  NCT00320385		RCTla/mBC - HER2 positive - 2nd Line (L2)lapatinib plus trastuzumablapatinib monotherapyPatients with HER2-positive mBC who had experienced progression on prior trastuzumab-based therapy. Patients must have received prior anthracycline- and taxane-based regimens in either the adjuvant or metastatic setting.148 / 148some concern
 suggested
  • suggested 26 % decrease in deaths (OS)
  • suggested 26 % decrease in progression or deaths (PFS) (PE)
versus trastuzumab plus capecitabine
lapatinib plus capecitabine
WJOG6110B/ELTOP, 2018
  UMIN000005219		RCTla/mBC - HER2 positive - 2nd Line (L2)lapatinib plus capecitabinetrastuzumab plus capecitabineWomen, aged 20yr or older, cith HER2-positive mBC or unresectable locally advanced BC who were previously treated with taxanes, with progression on trastuzumab-containing regimens43 / 43NA
 suggested
  • inconclusive 19 % decrease in progression or deaths (PFS) (PE)

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons